AI Terminal
Vetoquinol SA
Report Publication Announcement • Jan 15, 2025
1747_iss_2025-01-15_7f4aed07-4610-4b4d-a1a2-e1fe9a2832a2.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
PRESS RELEASE
Lure January 15th, 2025
2025 CALENDAR OF FINANCIAL COMMUNICATION
Vetoquinol published its calendar of financial communication for 2025.
| January 30, 2025 | 2024 Annual Sales (after market) |
|---|---|
| March 20, 2025 | 2024 Annual results (confcall after market) |
| April 24, 2025 | 2025 First quarter sales (after market) |
| May 22, 2025 | Annual shareholders' meeting |
| June 6, 2025 | Dividend payment |
| September 11, 2025 | 2025 First semester results (confcall after market) |
| October 28, 2025 | 2025 Third quarter sales (after market) |
Next update: Annual Sales 2024, January 30th, 2025 after market close
FOR MORE INFORMATION, CONTACT:
VETOQUINOL
Investor Relations Fanny Toillon Tel.: +33 (0)3 84 62 59 88 [email protected] ABOUT VETOQUINOL
Vetoquinol is a leading international player in animal health, with operations in Europe, the Americas and Asia/Pacific.
Independent and a pure player, Vetoquinol innovates, develops and markets veterinary medicines and non-medicated products for farm animals (cattle, pigs) and pets (dogs, cats).
Since its creation in 1933, Vetoquinol has combined innovation and geographic diversification. The strengthening of the product portfolio and acquisitions in high-potential territories ensure hybrid growth for the Group. At June 30, 2024, Vetoquinol employed 2,519 people.
Vetoquinol has been listed on Euronext Paris since 2006 (mnemonic code: VETO).
The Vetoquinol share is eligible for the French PEA and PEA-PME personal equity plans.
VETOQUINOL Magny-Vernois 70200 Lure - France
www.vetoquinol.com